Worth Venture Partners LLC bought a new stake in Kamada Ltd. (NASDAQ:KMDA) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 51,322 shares of the biotechnology company’s stock, valued at approximately $246,000. Worth Venture Partners LLC owned 0.14% of Kamada as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors have also made changes to their positions in KMDA. Renaissance Technologies LLC boosted its position in shares of Kamada by 16.7% in the first quarter. Renaissance Technologies LLC now owns 264,800 shares of the biotechnology company’s stock valued at $1,801,000 after acquiring an additional 37,800 shares during the period. Edmond DE Rothschild Holding S.A. boosted its position in shares of Kamada by 10.5% in the second quarter. Edmond DE Rothschild Holding S.A. now owns 42,200 shares of the biotechnology company’s stock valued at $251,000 after acquiring an additional 4,000 shares during the period. Vanguard Group Inc. boosted its position in shares of Kamada by 6.5% in the second quarter. Vanguard Group Inc. now owns 468,390 shares of the biotechnology company’s stock valued at $2,810,000 after acquiring an additional 28,382 shares during the period. Nexthera Capital LP bought a new stake in shares of Kamada in the second quarter valued at about $1,805,000. Finally, Navellier & Associates Inc bought a new stake in shares of Kamada in the second quarter valued at about $303,000. 7.39% of the stock is owned by institutional investors.
A number of equities research analysts have recently issued reports on the stock. ValuEngine cut shares of Kamada from a “hold” rating to a “sell” rating in a research report on Friday, September 1st. Zacks Investment Research raised shares of Kamada from a “sell” rating to a “hold” rating in a research report on Tuesday, August 15th. Jefferies Group LLC reissued a “buy” rating and issued a $7.00 target price (down previously from $9.00) on shares of Kamada in a research report on Wednesday, August 2nd. Finally, TheStreet cut shares of Kamada from a “c-” rating to a “d+” rating in a research report on Tuesday, August 1st. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and two have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $8.50.
Kamada Ltd. (KMDA) traded up $0.20 on Tuesday, reaching $4.65. 161,800 shares of the company traded hands, compared to its average volume of 73,016. Kamada Ltd. has a 1-year low of $3.75 and a 1-year high of $8.61. The company has a debt-to-equity ratio of 0.02, a current ratio of 2.85 and a quick ratio of 1.95.
Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy.
Want to see what other hedge funds are holding KMDA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kamada Ltd. (NASDAQ:KMDA).
Receive News & Ratings for Kamada Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.